PT  - JOURNAL ARTICLE
AU  - Dicks, Ed M.
AU  - Tyrer, Jonthan P.
AU  - Ezquina, Suzana
AU  - Jones, Michelle
AU  - Baierl, John
AU  - Peng, Pei-Chen
AU  - Diaz, Michael
AU  - Goode, Ellen
AU  - Winham, Stacey J
AU  - Dörk, Thilo
AU  - Van Gorp, Toon
AU  - De Fazio, Ana
AU  - Bowtell, David
AU  - Odunsi, Kunle
AU  - Moysich, Kirsten
AU  - Pavanello, Marina
AU  - Campbell, Ian
AU  - Brenton, James D.
AU  - Ramus, Susan J.
AU  - Gayther, Simon A.
AU  - Pharoah, Paul D. P.
TI  - Exome sequencing identifies <em>HELB</em> as a novel susceptibility gene for non-mucinous, non-high-grade-serous epithelial ovarian cancer
AID  - 10.1101/2024.04.02.24304968
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.04.02.24304968
4099  - http://medrxiv.org/content/early/2024/04/03/2024.04.02.24304968.short
4100  - http://medrxiv.org/content/early/2024/04/03/2024.04.02.24304968.full
AB  - Rare, germline loss-of-function variants in a handful of genes that encode DNA repair proteins have been shown to be associated with epithelial ovarian cancer with a stronger association for the high-grade serous hiostotype. The aim of this study was to collate exome sequencing data from multiple epithelial ovarian cancer case cohorts and controls in order to systematically evaluate the role of coding, loss-of-function variants across the genome in epithelial ovarian cancer risk. We assembled exome data for a total of 2,573 non-mucinous cases (1,876 high-grade serous and 697 non-high grade serous) and 13,925 controls. Harmonised variant calling and quality control filtering was applied across the different data sets. We carried out a gene-by-gene simple burden test for association of rare loss-of-function variants (minor allele frequency < 0.1%) with all non-mucinous ovarian cancer, high grade serous ovarian cancer and non-high grade serous ovarian cancer using logistic regression adjusted for the top four principal components to account for cryptic population structure and genetic ancestry. Seven of the top 10 associated genes were associations of the known ovarian cancer susceptibility genes BRCA1, BRCA2, BRIP1, RAD51C, RAD51D, MSH6 and PALB2 (false discovery probability < 0.1). A further four genes (HELB, OR2T35, NBN and MYO1A) had a false discovery rate of less than 0.1. Of these, HELB was most strongly associated with the non-high grade serous histotype (P = 1.3x10−6, FDR = 9.1x10−4). Further support for this association comes from the observation that loss of function variants in this gene are also associated with age at natural menopause and Mendelian randomisation analysis shows an association between genetically predicted age at natural menopause and endometrioid ovarian cancer, but not high-grade serous ovarian cancer.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCancer Research UK (PRCPJT-May21\100006); Cancer Australia Priority-driven Collaborative Cancer Research Scheme (APP1147276 to SJR); NIH (P30CA015083, P50CA136939, R01CA178535, R01CA248288 and R00CA256519). TD is supported by the German Research Foundation (Do761/15-1); SJR is supported by National Health and Medical Research Council (NHMRC) of Australia (2009840)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:East of England Cambridge South Research Ethics Committee of the UK National Research Ethics Service and the Institutional Review Board of University of Southern California Health Sciences Campus gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes